Hemab’s Analyst Consensus Is Wrong. Here’s Why.

The Current State of Play

Hemab Therapeutics (COAG.O) is facing a challenging technical environment, with the stock currently in a downtrend showing a -7.92% price movement over the recent period, signaling that short-term momentum is firmly against buyers.